Northland Securities analyst Carl Byrnes maintained a Buy rating on Nabriva (NBRV) today and set a price target of $12.50. The company’s shares opened today at $2.18.
According to TipRanks.com, Byrnes ‘ ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -7.9% and a 26.8% success rate. Byrnes covers the Healthcare sector, focusing on stocks such as Aridis Pharmaceuticals Inc, Adamas Pharmaceuticals, and Flexion Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Nabriva with a $7.70 average price target, a 253.2% upside from current levels. In a report issued on May 1, Needham also maintained a Buy rating on the stock with a $10 price target.
See today’s analyst top recommended stocks >>
Based on Nabriva’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $30.83 million. In comparison, last year the company had a GAAP net loss of $13.34 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Nabriva Therapeutics Plc is a clinical stage biopharmaceutical company, which engages in the research and development of novel antibiotics to treat serious infections. Its product pipeline includes Lefamulin, CONTEPO, and BC-7013. The company was founded in October 2005 and is headquartered in Dublin, Ireland.
